Clearmind Medicine Inc. (NASDAQ:CMND) Short Interest Down 80.3% in May

Clearmind Medicine Inc. (NASDAQ:CMND) was the target of a large drop in short interest in the month of May. As of May 29th, there was short interest totaling 40,505 shares, a drop of 80.3% from the May 14th total of 205,330 shares. Based on an average daily trading volume, of 5,667,197 shares, the days-to-cover ratio is currently 0.0 days. Currently, 4.0% of the company’s shares are short sold.

Clearmind Medicine Stock Performance

Shares of NASDAQ CMND traded up $0.19 during midday trading on Thursday, hitting $3.39. 132,325 shares of the company traded hands, compared to its average volume of 1,162,969. Clearmind Medicine has a 12-month low of $2.10 and a 12-month high of $524.00. The firm has a market cap of $3.46 million, a P/E ratio of -0.02 and a beta of 0.64. The stock has a 50-day moving average price of $6.51 and a 200 day moving average price of $17.51.

Clearmind Medicine (NASDAQ:CMND) last released its earnings results on Thursday, March 12th. The company reported ($33.20) EPS for the quarter.

Analyst Ratings Changes

Separately, Wall Street Zen upgraded Clearmind Medicine to a “sell” rating in a report on Saturday, May 23rd.

Clearmind Medicine Company Profile

Clearmind Medicine, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel psychoplastogen-based therapeutics for neuropsychiatric and neurodegenerative disorders. The company leverages a proprietary chemistry platform to design small-molecule compounds that promote rapid and sustained neural plasticity without the hallucinogenic effects typically associated with psychedelic agents. By targeting fundamental mechanisms of synaptic growth and repair, Clearmind aims to address conditions ranging from mood and anxiety disorders to cognitive impairment in dementia.

Clearmind’s pipeline includes multiple preclinical and early clinical candidates.